- Home
- IMRN vs TXMD Comparison
IMRN vs TXMD Comparison
Compare IMRN & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- TXMD
- Stock Information
- Founded
- IMRN 1994
- TXMD 2008
- Country
- IMRN Australia
- TXMD United States
- Employees
- IMRN N/A
- TXMD N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- TXMD Health Care
- Exchange
- IMRN Nasdaq
- TXMD Nasdaq
- Market Cap
- IMRN 15.0M
- TXMD 12.8M
- IPO Year
- IMRN N/A
- TXMD N/A
- Fundamental
- Price
- IMRN $2.15
- TXMD $1.06
- Analyst Decision
- IMRN Strong Buy
- TXMD
- Analyst Count
- IMRN 1
- TXMD 0
- Target Price
- IMRN $5.00
- TXMD N/A
- AVG Volume (30 Days)
- IMRN 21.6K
- TXMD 852.1K
- Earning Date
- IMRN 02-26-2025
- TXMD 11-12-2024
- Dividend Yield
- IMRN N/A
- TXMD N/A
- EPS Growth
- IMRN N/A
- TXMD N/A
- EPS
- IMRN N/A
- TXMD N/A
- Revenue
- IMRN $3,271,194.00
- TXMD $1,596,000.00
- Revenue This Year
- IMRN N/A
- TXMD $605.07
- Revenue Next Year
- IMRN N/A
- TXMD $1.11
- P/E Ratio
- IMRN N/A
- TXMD N/A
- Revenue Growth
- IMRN 171.67
- TXMD N/A
- 52 Week Low
- IMRN $1.59
- TXMD $0.70
- 52 Week High
- IMRN $5.96
- TXMD $2.75
- Technical
- Relative Strength Index (RSI)
- IMRN 56.18
- TXMD 44.74
- Support Level
- IMRN $1.85
- TXMD $0.99
- Resistance Level
- IMRN $2.20
- TXMD $1.14
- Average True Range (ATR)
- IMRN 0.22
- TXMD 0.27
- MACD
- IMRN 0.01
- TXMD -0.00
- Stochastic Oscillator
- IMRN 57.47
- TXMD 20.69
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.